E
XORTX Therapeutics Inc.
XRTX.V
TSX
E
Sell
11/22/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D- on 11/22/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 15.36 to 9.28.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D- on 11/22/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 15.36 to 9.28.
D
Sell
11/9/2023Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D- from E+ on 11/9/2023 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D- from E+ on 11/9/2023 due to an increase in the volatility index.
E
Sell
10/13/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D- on 10/13/2023 due to a decline in the volatility index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D- on 10/13/2023 due to a decline in the volatility index.
D
Sell
8/22/2023Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D- from E+ on 8/22/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 30.32% from -$2.48M to -$1.73M, EBIT increased 11.23% from -$1.68M to -$1.49M, and earnings per share increased from -$0.1055 to -$0.094.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D- from E+ on 8/22/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 30.32% from -$2.48M to -$1.73M, EBIT increased 11.23% from -$1.68M to -$1.49M, and earnings per share increased from -$0.1055 to -$0.094.
E
Sell
8/2/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D- on 8/2/2023 due to a decline in the growth index and volatility index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D- on 8/2/2023 due to a decline in the growth index and volatility index.
D
Sell
7/18/2023Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D- from E+ on 7/18/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.94 to 13.25, operating cash flow increased 34.62% from -$3.8M to -$2.48M, and EBIT increased 31.42% from -$2.45M to -$1.68M.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D- from E+ on 7/18/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.94 to 13.25, operating cash flow increased 34.62% from -$3.8M to -$2.48M, and EBIT increased 31.42% from -$2.45M to -$1.68M.
E
Sell
4/10/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D+ on 4/10/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 299.4% from -$951.2 to -$3.8M, net income declined 79.53% from -$1.2M to -$2.15M, and earnings per share declined from -$0.0922 to -$0.1503.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E+ from D+ on 4/10/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 299.4% from -$951.2 to -$3.8M, net income declined 79.53% from -$1.2M to -$2.15M, and earnings per share declined from -$0.0922 to -$0.1503.
D
Sell
4/5/2023Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 4/5/2023 due to an increase in the volatility index and valuation index.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 4/5/2023 due to an increase in the volatility index and valuation index.
D
Sell
3/16/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 3/16/2023 due to a decline in the volatility index and total return index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 3/16/2023 due to a decline in the volatility index and total return index.
D
Sell
3/1/2023Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 3/1/2023 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 3/1/2023 due to an increase in the volatility index.
D
Sell
2/9/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 2/9/2023 due to a decline in the volatility index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 2/9/2023 due to a decline in the volatility index.
D
Sell
1/24/2023Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 1/24/2023 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 1/24/2023 due to an increase in the volatility index.
D
Sell
1/4/2023Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 1/4/2023 due to a decline in the volatility index, total return index and efficiency index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 1/4/2023 due to a decline in the volatility index, total return index and efficiency index.
D
Sell
12/6/2022Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D+ from C- on 12/6/2022 due to a decline in the volatility index, valuation index and total return index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D+ from C- on 12/6/2022 due to a decline in the volatility index, valuation index and total return index.
C
Hold
11/17/2022Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to C- from D on 11/17/2022 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 49.47% from -$1.88M to -$950.6, EBIT increased 10.45% from -$2.21M to -$1.98M, and earnings per share increased from -$0.0954 to -$0.0921.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to C- from D on 11/17/2022 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 49.47% from -$1.88M to -$950.6, EBIT increased 10.45% from -$2.21M to -$1.98M, and earnings per share increased from -$0.0954 to -$0.0921.
D
Sell
11/11/2022Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.2081 to -$0.0954, operating cash flow increased 24.83% from -$2.5M to -$1.88M, and EBIT increased 15.42% from -$2.61M to -$2.21M.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.2081 to -$0.0954, operating cash flow increased 24.83% from -$2.5M to -$1.88M, and EBIT increased 15.42% from -$2.61M to -$2.21M.
D
Sell
4/20/2022Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. Operating cash flow declined 5,018.76% from -$61.3 to -$3.14M, and EBIT declined 432.22% from -$197.7 to -$1.05M.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. Operating cash flow declined 5,018.76% from -$61.3 to -$3.14M, and EBIT declined 432.22% from -$197.7 to -$1.05M.
D
Sell
12/21/2021Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 12/21/2021 due to a large decline in the total return index and volatility index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D from D+ on 12/21/2021 due to a large decline in the total return index and volatility index.
D
Sell
12/2/2021Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 12/2/2021 due to an increase in the valuation index.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D+ from D on 12/2/2021 due to an increase in the valuation index.
D
Sell
11/23/2021Upgraded
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
XORTX Therapeutics Inc. (XRTX.V) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
7/13/2021Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 7/13/2021 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 7/13/2021 due to an increase in the volatility index.
D
Sell
6/21/2021Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 6/21/2021 due to a decline in the total return index and volatility index.
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 6/21/2021 due to a decline in the total return index and volatility index.
D
Sell
2/5/2021Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 2/5/2021 due to a large increase in the total return index and volatility index.
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 2/5/2021 due to a large increase in the total return index and volatility index.
D
Sell
1/13/2021Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E+ on 1/13/2021 due to an increase in the volatility index, solvency index and valuation index.
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E+ on 1/13/2021 due to an increase in the volatility index, solvency index and valuation index.
E
Sell
11/16/2020Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to E+ from D- on 11/16/2020 due to a decline in the total return index and solvency index.
XORTX Therapeutics Inc. (XRX) was downgraded to E+ from D- on 11/16/2020 due to a decline in the total return index and solvency index.
D
Sell
9/2/2020Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 9/2/2020 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.0004 to -$0.0072, and EBIT declined 161.67% from -$87.4 to -$228.7.
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 9/2/2020 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.0004 to -$0.0072, and EBIT declined 161.67% from -$87.4 to -$228.7.
D
Sell
5/20/2020Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 5/20/2020 due to a large increase in the growth index, volatility index and total return index.
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 5/20/2020 due to a large increase in the growth index, volatility index and total return index.
D
Sell
4/30/2020Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 4/30/2020 due to a major decline in the solvency index, growth index and valuation index. Operating cash flow declined 919.59% from $9.7 to -$79.5, debt to equity increased from -0.49 to -0.24, and the quick ratio declined from 0.11 to 0.06.
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 4/30/2020 due to a major decline in the solvency index, growth index and valuation index. Operating cash flow declined 919.59% from $9.7 to -$79.5, debt to equity increased from -0.49 to -0.24, and the quick ratio declined from 0.11 to 0.06.
D
Sell
4/14/2020Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 4/14/2020 due to an increase in the total return index.
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 4/14/2020 due to an increase in the total return index.
D
Sell
3/30/2020Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 3/30/2020 due to a decline in the volatility index and total return index.
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 3/30/2020 due to a decline in the volatility index and total return index.
D
Sell
3/5/2020Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 3/5/2020 due to an increase in the volatility index, total return index and valuation index.
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 3/5/2020 due to an increase in the volatility index, total return index and valuation index.
D
Sell
2/19/2020Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 2/19/2020 due to a decline in the total return index, volatility index and growth index.
XORTX Therapeutics Inc. (XRX) was downgraded to D- from D on 2/19/2020 due to a decline in the total return index, volatility index and growth index.
D
Sell
11/29/2019Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 11/29/2019 due to a large increase in the growth index, efficiency index and valuation index. Operating cash flow increased 132.33% from -$30 to $9.7, net income increased 14.03% from -$116.2 to -$99.9, and earnings per share increased from -$0.0018 to -$0.0016.
XORTX Therapeutics Inc. (XRX) was upgraded to D from D- on 11/29/2019 due to a large increase in the growth index, efficiency index and valuation index. Operating cash flow increased 132.33% from -$30 to $9.7, net income increased 14.03% from -$116.2 to -$99.9, and earnings per share increased from -$0.0018 to -$0.0016.
D
Sell
5/1/2019Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E+ on 5/1/2019 due to an increase in the growth index, total return index and solvency index. EBIT increased 57.18% from -$210.2 to -$90, earnings per share increased from -$0.0037 to -$0.0018, and operating cash flow increased 38.15% from -$152.3 to -$94.2.
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E+ on 5/1/2019 due to an increase in the growth index, total return index and solvency index. EBIT increased 57.18% from -$210.2 to -$90, earnings per share increased from -$0.0037 to -$0.0018, and operating cash flow increased 38.15% from -$152.3 to -$94.2.
E
Sell
4/18/2019Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to E+ from D- on 4/18/2019 due to a decline in the volatility index and total return index.
XORTX Therapeutics Inc. (XRX) was downgraded to E+ from D- on 4/18/2019 due to a decline in the volatility index and total return index.
D
Sell
4/3/2019Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E+ on 4/3/2019 due to a noticeable increase in the total return index and volatility index.
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E+ on 4/3/2019 due to a noticeable increase in the total return index and volatility index.
E
Sell
11/30/2018Downgrade
XORTX Therapeutics Inc. (XRX) was downgraded to E+ from D- on 11/30/2018 due to a large decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0034 to -$0.0037, and EBIT declined 4.01% from -$202.1 to -$210.2.
XORTX Therapeutics Inc. (XRX) was downgraded to E+ from D- on 11/30/2018 due to a large decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0034 to -$0.0037, and EBIT declined 4.01% from -$202.1 to -$210.2.
D
Sell
10/1/2018Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E on 10/1/2018 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$0.0417 to -$0.0034, operating cash flow increased 71.79% from -$756.5 to -$213.4, and EBIT increased 41.16% from -$343.5 to -$202.1.
XORTX Therapeutics Inc. (XRX) was upgraded to D- from E on 10/1/2018 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$0.0417 to -$0.0034, operating cash flow increased 71.79% from -$756.5 to -$213.4, and EBIT increased 41.16% from -$343.5 to -$202.1.
E
Sell
7/2/2018Upgraded
XORTX Therapeutics Inc. (XRX) was upgraded to E from E- on 7/2/2018 due to an increase in the solvency index and total return index. The quick ratio increased from 0.06 to 1.06.
XORTX Therapeutics Inc. (XRX) was upgraded to E from E- on 7/2/2018 due to an increase in the solvency index and total return index. The quick ratio increased from 0.06 to 1.06.
E
Sell
4/6/2018None
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E- from U on 04/06/2018.
XORTX Therapeutics Inc. (XRTX.V) was downgraded to E- from U on 04/06/2018.
